A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

PURPOSE: Oral administration of the alkylating agent cyclophosphamide at low doses, metronomic dosing, is well tolerated, with efficacy in multiple tumor types. Poly(ADP-ribose) polymerase (PARP) inhibition potentiates effects of cyclophosphamide in preclinical models. We conducted a phase I trial o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kummar, Shivaani, Ji, Jiuping, Morgan, Robert, Lenz, Heinz-Josef, Puhalla, Shannon L., Belani, Chandra P., Gandara, David R., Allen, Deborah, Kiesel, Brian, Beumer, Jan H., Newman, Edward M., Rubinstein, Larry, Chen, Alice, Zhang, Yiping, Wang, Lihua, Kinders, Robert J., Parchment, Ralph E., Tomaszewski, Joseph E., Doroshow, James H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3306481/
https://ncbi.nlm.nih.gov/pubmed/22307137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-2821
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados